CERo Therapeutics Holdings, Inc. (CEROW) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerCERo Therapeutics Holdings, Inc. (CEROW) trades at $0.00214. CERo Therapeutics Holdings, Inc. is an immunotherapy company focused on developing engineered T cell therapeutics for cancer treatment. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for CEROW: CEROW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
CERo Therapeutics Holdings, Inc. (CEROW) Healthcare & Pipeline Overview
CERo Therapeutics Holdings, Inc. is a biotechnology company specializing in the development of engineered T-cell therapies for cancer, particularly hematologic malignancies. Their innovative approach targets the 'Eat Me' signal on tumor cells, positioning them within the competitive immunotherapy landscape.
What Is the Investment Thesis for CEROW?
CERo Therapeutics Holdings, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on engineered T cell therapies targeting the 'Eat Me' signal in hematologic malignancies offers a novel approach with the potential for significant clinical impact. Key value drivers include the successful advancement of their lead program through preclinical and clinical development, securing strategic partnerships, and demonstrating superior efficacy compared to existing treatments. However, the company's early stage of development, limited financial resources (Market Cap: $0.00B), and the inherent risks associated with drug development pose substantial challenges. The negative profit margin of -1215.6% highlights the need for significant future funding. Successful clinical trials and regulatory approvals are critical for realizing the company's potential.
Based on FMP financials and quantitative analysis
CEROW Key Highlights
Focus on engineered T cell therapeutics for cancer treatment, specifically hematologic malignancies.
- Lead program targets the 'Eat Me' signal upregulated on B cell and myeloid tumors.
- Based in South San Francisco, a hub for biotechnology innovation.
- Early-stage development company focused on preclinical research and development.
- Gross Margin of -19.6% indicates significant costs associated with research and development.
Who Are CEROW's Competitors?
CEROW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AIMD Ainos, Inc. | $1.35 | +4.08% | $9.96M | — |
| BDRX Biodexa Pharmaceuticals Plc | $0.62 | -2.01% | — | |
| BIVI BioVie Inc. | $1.46 | -0.68% | $11.0M | — |
| CMMB Chemomab Therapeutics Ltd. | $1.43 | +10.00% | $8.80M | 30 5-pillar |
| NVO Novo Nordisk A/S | $37.32 | -0.21% | $166B | 91 5-pillar |
| VRTX Vertex Pharmaceuticals Incorporated | $504.73 | -0.40% | $128B | 97 5-pillar |
| REGN Regeneron Pharmaceuticals, Inc. | $735.20 | +0.05% | $75.7B | 94 5-pillar |
| ARGX argenx SE | $919.21 | -1.79% | $57.2B | 97 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CEROW's Key Strengths?
Novel approach targeting the 'Eat Me' signal in cancer cells.
- Expertise in engineered T cell therapy development.
- Potential for personalized medicine applications.
- Strategic location in a biotechnology hub.
What Are CEROW's Weaknesses?
Early-stage development with limited clinical data.
- Dependence on external funding and partnerships.
- Small team size and limited resources (8 employees).
- Negative profit margin and limited revenue.
What Are the Key Risks for CEROW?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or unexpected side effects.
- Regulatory delays or rejection of therapy approval.
- Competition from established players in the immunotherapy market.
- Dependence on external funding and partnerships.
- Patent disputes or intellectual property infringement.
What Are CEROW's Competitive Advantages?
- Proprietary engineered T cell technology targeting the 'Eat Me' signal.
- Strong intellectual property protection through patents.
- Expertise in T cell engineering and cancer immunotherapy.
- Potential for personalized medicine approach tailored to individual patients.
What Does CEROW Do?
CERo Therapeutics Holdings, Inc., founded to revolutionize cancer treatment, is an immunotherapy company dedicated to advancing the development of engineered T cell therapeutics. The company's primary focus is on creating innovative therapies for hematologic malignancies. Their lead program targets an 'Eat Me' signal, a mechanism upregulated on B cell and myeloid tumors that allows cancer cells to evade the immune system. By engineering T cells to recognize and attack this signal, CERo aims to provide more effective and targeted cancer treatments. Based in South San Francisco, California, a hub for biotechnology innovation, CERo is strategically positioned to attract top talent and collaborate with leading research institutions. The company is currently in the early stages of development, focusing on preclinical research and development to advance its lead program towards clinical trials. CERo's commitment to pioneering T cell therapies underscores its mission to improve outcomes for patients battling cancer. The company's approach reflects a growing trend in cancer immunotherapy, leveraging the body's own immune system to fight the disease.
What Products and Services Does CEROW Offer?
- Develop engineered T cell therapeutics for cancer treatment.
- Target the 'Eat Me' signal on cancer cells to enhance immune response.
- Focus on hematologic malignancies, such as B cell and myeloid tumors.
- Conduct preclinical research and development to advance therapies.
- Seek to improve outcomes for patients battling cancer through innovative immunotherapy.
- Pioneer T cell therapies leveraging the body's own immune system.
How Does CEROW Make Money?
- Develop and patent novel engineered T cell therapies.
- Out-license or partner with pharmaceutical companies for clinical development and commercialization.
- Potentially manufacture and sell therapies directly, pending regulatory approval.
- Generate revenue through upfront payments, milestone payments, and royalties.
What Industry Does CEROW Operate In?
CERo Therapeutics Holdings, Inc. operates within the rapidly evolving biotechnology industry, specifically in the cancer immunotherapy market. This market is characterized by intense competition and a high degree of innovation, with companies racing to develop more effective and targeted cancer treatments. CERo's focus on engineered T cell therapies aligns with a key trend in the industry, leveraging the body's own immune system to fight cancer. Competitors like AIMD, BDRX, BIVI, CMMB, and GLMD are also active in the immunotherapy space, highlighting the competitive landscape.
Who Are CEROW's Key Customers?
- Cancer patients suffering from hematologic malignancies.
- Hospitals and oncology clinics providing cancer treatment.
- Pharmaceutical companies seeking to expand their oncology portfolios.
- Research institutions and universities involved in cancer research.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
- ● This is a warrant, not an operating company
Company Profile
CERo Therapeutics Holdings, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Christopher Ehrlich. CEROW has traded publicly since 2024.
Key Financial Metrics
Return on equity for CERo Therapeutics Holdings, Inc. stands at 131.1%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.05 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
CERo Therapeutics Holdings, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Earnings Track Record
CERo Therapeutics Holdings, Inc. has beaten Wall Street's EPS estimate in 3 of its last 6 reported quarters — more hits than misses. Reported results have landed about 169.6% below estimates on average.
Forward Outlook
Wall Street analysts project CERo Therapeutics Holdings, Inc. revenue of about $0 for fiscal 2026, with EPS near $-2.50.
Insider Activity
12 transactions · 0 purchases, 0 sales, 12 other transactions · 9 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
CEROW Financials
Bull Case vs Bear Case
Bull Case
- Novel approach targeting the 'Eat Me' signal in cancer cells.
- Expertise in engineered T cell therapy development.
- Potential for personalized medicine applications.
- Strategic location in a biotechnology hub.
Bear Case
- Early-stage development with limited clinical data.
- Dependence on external funding and partnerships.
- Small team size and limited resources (8 employees).
- Negative profit margin and limited revenue.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CEROW Latest News
No recent news available for CEROW.
CEROW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CEROW.
Price Targets
Wall Street price target analysis for CEROW.
CEROW MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CEROW; grades run from A+ (80-100) to F (below 30).
Leadership: Christopher Ehrlich
CEO
Christopher Ehrlich serves as the CEO of CERo Therapeutics Holdings, Inc. His background encompasses experience in managing and leading biotechnology companies, with a focus on early-stage development. He brings a strategic vision to the company, guiding its efforts in developing innovative cancer therapies. His leadership is crucial for navigating the complexities of the biotechnology industry and securing funding for research and development. He is responsible for the overall direction and performance of the company.
Track Record: As CEO, Christopher Ehrlich is focused on advancing CERo's lead program through preclinical development and preparing for clinical trials. His strategic decisions are centered on securing partnerships, attracting investment, and building a strong team. His leadership is essential for achieving key milestones and driving the company's growth. He manages a small team of 8 employees.
CEROW OTC Market Information
CEROW trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
Common Questions About CEROW (Healthcare)
What do analysts say about CEROW stock?
As of March 17, 2026, there is no available analyst coverage for CEROW stock. The company's small market capitalization ($0.00B) and early stage of development may limit analyst interest.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.